Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNoticing a small drop of liquid on your skin after a Mounjaro injection is common and, in most cases, normal. The KwikPen delivers a precise dose into the subcutaneous tissue; a tiny amount of fluid at the injection site afterwards does not reliably indicate that the dose was lost. That said, the NHS tirzepatide guidance and the medicine's patient leaflet are your definitive references for what to do if you have concerns — and if you see this happening regularly, it is worth raising with your prescriber. Mounjaro is a prescription-only medicine; clinical oversight before and throughout treatment matters.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The Mounjaro KwikPen contains four weekly doses, each delivered by pressing the button until a click is felt and then holding the pen in place. According to the summary of product characteristics published on the eMC (electronic Medicines Compendium), a small amount of liquid remaining inside the pen after each injection is a normal feature of the pen's design, not evidence that the dose failed. The medication is released into the subcutaneous layer (the fatty tissue just beneath the skin) rather than sitting visibly at the surface.
When a tiny bead of liquid appears on the skin, it most often comes from the needle track itself as the device withdraws, or from a small amount of tissue fluid drawn up by capillary action. It is not the same as the dose escaping before it was absorbed. Our prescribers field this question most weeks, and the short answer is consistent: a single small drop does not mean you need to repeat the injection.
If you are curious about why there is liquid left in your Mounjaro pen after injecting, the detail on what liquid left in the Mounjaro pen actually means covers that separately.
Injection technique has a genuine effect on how much, if any, fluid appears at the skin surface. The NHS guidance on tirzepatide echoes the patient information leaflet in recommending a clean, dry site, a consistent 90-degree angle for most users, and (critically) keeping the pen pressed firmly against the skin for a full ten seconds after the click before withdrawing. Lifting the pen early is the most common reason a visible drop appears; the medication has not yet fully dispersed into the subcutaneous layer when the needle exits.
Rotating sites also matters. Injecting repeatedly into the same small area can create localised skin changes (lipohypertrophy) that slow absorption and increase the chance of surface leakage. The licensed injection sites are the abdomen, the outer thigh, and the upper arm, rotate within and between them. Cleaning the skin with an alcohol swab beforehand and letting it dry completely before injecting removes surface oils that can make the needle track less clean.
If technique feels uncertain, a practical guide to the Mounjaro injection process walks through each step in detail.
One small bead of liquid after a single injection: almost certainly nothing to act on. A pattern of visible leakage after every injection, or a noticeably larger amount of fluid on the skin, is a different situation. At that point, it is worth reviewing your technique step by step and, if the issue persists, contacting your prescriber rather than simply repeating the dose.
Repeating a dose on the assumption it was lost is not advised without clinical guidance. Taking more than the prescribed weekly dose carries real risks, including more pronounced gastrointestinal side effects and potential issues with blood sugar in people who also manage diabetes. If you are weighing up whether a dose delivered properly, the guidance on checking your pen after an injection can help you interpret what you see.
There are also a few practical things to eliminate first: was the pen stored correctly in the fridge between doses? Was the needle changed before this injection? A blocked or damaged needle is an uncommon but real cause of incomplete delivery. Replacing needles as instructed in the leaflet (one per injection) and storing the pen between 2°C and 8°C protects both the dose and the device. For needle supplies, compatible replacement needles are available if you need them.
Uncertainty is understandable, particularly in the early weeks of treatment when the whole process is new. The clear clinical position, reflected in the patient information leaflet and reinforced by NHS guidance, is: do not inject a second dose to compensate. Instead, continue your usual weekly schedule and raise the concern at your next prescriber contact.
If this is happening at nume (sorry, at a service like ours) your aftercare team is available seven days a week for exactly these questions. There is no need to make a decision in isolation. You can also explore the broader Mounjaro treatment overview for context on how the medicine works, or check the cost and eligibility picture on the Mounjaro cost page if you are still weighing up whether to start. When you are ready to speak to a prescriber directly, start your free consultation and a GPhC-registered clinician will review your case the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.